Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961776 · ClinicalTrials.gov registry record
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
A clinical trial of Rectal Adenocarcinoma, sponsored by Institut Paoli-Calmettes.
- Recruiting
- Registry status
- 39
- Enrollment target
- 2
- Study locations
NCT03961776 is a study of Rectal Adenocarcinoma that is actively recruiting participants, run by Institut Paoli-Calmettes. The registered enrollment target is 39 participants, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03961776, a study of Rectal Adenocarcinoma, is actively recruiting participants, sponsored by Institut Paoli-Calmettes.
- RECRUITING
- Registry status
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
Conditions Studied
Interventions
- DEVICE MRI-guided radiotherapy by on-board DWI sequences
Study Locations (2)
California
- University of California Los Angeles (UCLA) - Los Angeles
Bouches Du Rhone
- Institut Paoli Calmettes - Marseille
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2027-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03961776
The ClinicalTrials.gov registry entry for NCT03961776 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (68% lower). The listed sponsor is Institut Paoli-Calmettes, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which MRI-guided radiotherapy by on-board DWI sequences is the first listed.
NCT03961776 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Bouches Du Rhone.
Frequently Asked Questions
What is clinical trial NCT03961776 about?
NCT03961776 is a clinical study titled "Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems". feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
What is the current status of trial NCT03961776?
This trial is currently recruiting. The enrollment target is 39 participants. The study started on 2020-06-08. Estimated completion is 2027-05.
What conditions does trial NCT03961776 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma.
What interventions are being tested in trial NCT03961776?
The interventions under investigation include: MRI-guided radiotherapy by on-board DWI sequences (DEVICE).
Who is sponsoring clinical trial NCT03961776?
This trial is sponsored by Institut Paoli-Calmettes, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03961776 being conducted?
This trial has 2 study locations across California, Bouches Du Rhone. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITING · Phase 3
-
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
RECRUITING · Phase 2
-
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
RECRUITING · Early Phase 1
-
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.